GLP-1 Chart

Ozempic vs Wegovy

Ozempic vs Wegovy: both brands hold the same medicine, semaglutide, from the same maker, Novo Nordisk.

Prefer

Last updated October 18, 2026. Labels read October 6, 2026.

Learn

More about this page

Semaglutide acts on the GLP-1 receptor. GLP-1 is a gut hormone that plays a part in blood sugar and in how much a person eats. What differs is the label. Each brand has its own FDA label, and the two labels list different approved uses. Wegovy also comes as a tablet.

Source: Drucker DJ, Cell Metabolism 2018, PMID 29617641.

The two labels side by side

Label factOzempicWegovy
Medicine (molecule)semaglutidesemaglutide
TypeGLP-1
OZEMPIC is a glucagon-like peptide 1 (GLP-1) receptor agonist
GLP-1
WEGOVY is a glucagon-like peptide-1 (GLP-1) receptor agonist
Maker on the labelNovo Nordisk Pharmaceutical Industries, LPNovo Nordisk Pharmaceutical Industries, LP
Taken asInjection: pen or prefilled syringe single-patient-use pens ... single-dose prefilled syringeInjection: pen single-patient-use pen (WEGOVY FlexTouch)
Tablet: tablet Take one WEGOVY tablet orally
How often, per labelOnce weekly Administer OZEMPIC once weekly, on the same day each weekOnce weekly (injection) Administer WEGOVY injection once weekly, on the same day each week
Once daily (tablet) Take one WEGOVY tablet orally once daily
Approved uses, per label
  • Blood sugar in type 2 diabetes as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
  • Lower risk of major cardiovascular events to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease
  • Kidney disease with type 2 diabetes to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease
  • Lower risk of major cardiovascular events to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight
  • Excess body weight, long term (injection only) to reduce excess body weight and maintain weight reduction long term in ... adults and pediatric patients aged 12 years and older with obesity ... adults with overweight in the presence of at least one weight-related comorbid condition
  • Excess body weight, long term (tablets only) to reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight in the presence of at least one weight-related comorbid condition
  • MASH liver disease (injection only) for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults
Boxed warningYes WARNING: RISK OF THYROID C-CELL TUMORSYes WARNING: RISK OF THYROID C-CELL TUMORS
Label readOzempic label, version 20, effective June 1, 2026Wegovy label, version 19, effective June 18, 2026
FDA approval recordNDA209637, first approved December 5, 2017NDA215256, first approved June 4, 2021
NDA218316, first approved December 22, 2025

All rows are quoted straight from the two labels. Follow a label link to see the DailyMed version we used.

What the two labels share

  • The medicine. Both labels name semaglutide as the medicine.
  • The maker. Both labels name Novo Nordisk.
  • The shot. Both labels have a once weekly shot under the skin, given with a pen.
  • The boxed warning. The same boxed warning, about thyroid C-cell tumors, opens both labels.

Where the two labels differ

  • Approved uses. The Ozempic label is about adults with type 2 diabetes. It lists blood sugar control, a lower risk of major cardiovascular events (cardiovascular death, or a heart attack or stroke that is not fatal), and a kidney use. The Wegovy label lists excess body weight, lower risk of major cardiovascular events in adults with obesity or overweight, and a liver disease called MASH. MASH is listed for the shot only.
  • Ages. For the Wegovy shot, the weight use includes children 12 years and older with obesity. The Wegovy tablets and the Ozempic label list adults only.
  • Forms. Wegovy also comes as a once daily tablet. Ozempic tablets exist too, but they share a label with Rybelsus, not with the Ozempic shot. See the GLP-1 pill page.
  • FDA approval records. Ozempic was first approved in 2017. The Wegovy shot was first approved in 2021, and Wegovy tablets in 2025, as the table shows.

Using semaglutide products together

The Wegovy label has a limitation of use about other semaglutide products. Here it is in the label's own words.

Wegovy label, section 1, Limitations of UseConcomitant use of WEGOVY (semaglutide) tablets or WEGOVY (semaglutide) injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.

More side by side pages

For the two tirzepatide brands, see Mounjaro vs Zepbound. To put semaglutide next to tirzepatide, see tirzepatide vs semaglutide. Any other pair is in the GLP-1 comparison chart under "Compare two".

Questions

Is Ozempic the same as Wegovy?

Ozempic and Wegovy hold the same medicine, semaglutide, from the same maker. But they are different products with different FDA labels. The labels list different approved uses.

What is the difference between Ozempic and Wegovy?

The labels differ in approved uses, ages and forms. The Ozempic label covers adults with type 2 diabetes. The Wegovy label covers excess body weight and cardiovascular risk in adults with obesity or overweight. It also lists MASH and a weight use for teens 12 and older, for the shot only. Wegovy comes as a shot and a tablet.

Is Ozempic a GLP-1?

Yes, Ozempic is a GLP-1 medicine. The Ozempic label calls it a glucagon-like peptide 1 (GLP-1) receptor agonist.

Sources

4 sources with read dates
  1. Ozempic label on DailyMed, Novo Nordisk, version 20 of 2026-06-01, read 2026-10-06
  2. Wegovy label on DailyMed, Novo Nordisk, version 19 of 2026-06-18, read 2026-10-06
  3. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1, Drucker DJ, Cell Metabolism 2018, PMID 29617641, abstract read on PubMed 2026-10-06
  4. Drugs@FDA application records for NDA 209637, 215256 and 218316, US Food and Drug Administration, via the openFDA drugsfda API, read 2026-10-06